A dose of Eli Lilly’s diabetes drug Mounjaro has limited availability through February, according to the Food and Drug Administration’s website, due to an increase in demand. The health regulator’s website showed the 12.5 milligram dose of the injection will be available in limited amounts, while other doses of Mounjaro are available. (Reuters)
Samsung Biologics said its net profit fell 21.4% in Q4 2023 due largely to a one-off factor. The company said its quarterly sales reached an all-time high due largely to large-scale contract manufacturing deals with global big pharma companies, such as Pfizer and Novartis. (The Korea Times)
In a complete response letter, the FDA denied approval for a newer formulation of tesamorelin that Theratechnologies proposed as a treatment to reduce excess abdominal fat in patients with HIV and lipodystrophy. The Montreal-based drugmaker said it plans to address the FDA’s request and intends to pursue approval of this newer formulation of tesamorelin. (Seeking Alpha)
Silo Pharma said its Alzheimer’s disease therapeutic SPC-14 showed positive efficacy in small animals. The biopharmaceutical company said data from a study conducted in collaboration with Columbia University showed SPC-14 was effective against luteinizing hormone stress in attenuating learned helplessness, perseverative behavior, and hyponeophagia. (MarketWatch)
A blog post from Harvard Health detailed why prescription drugs cost so much. The piece outlines ways to minimize what we spend on prescription drugs, how we got to this juncture where some medicines cost more than $1 million per dose and what changes are needed in our pricey medication-industrial-complex. (Chicago Tribune)
Click here to see yesterday’s Five things for pharma marketers to know.
